• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英国和安大略省老年人口服皮质类固醇不同处方模式与骨折预防护理的关联。

Association of Different Prescribing Patterns for Oral Corticosteroids With Fracture Preventive Care Among Older Adults in the UK and Ontario.

机构信息

Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.

Women's College Research Institute, Women's College Hospital, Toronto, Canada.

出版信息

JAMA Dermatol. 2023 Sep 1;159(9):961-969. doi: 10.1001/jamadermatol.2023.2495.

DOI:10.1001/jamadermatol.2023.2495
PMID:37556153
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10413212/
Abstract

IMPORTANCE

Identifying and mitigating modifiable gaps in fracture preventive care for people with relapsing-remitting conditions such as eczema, asthma, and chronic obstructive pulmonary disease who are prescribed high cumulative oral corticosteroid doses may decrease fracture-associated morbidity and mortality.

OBJECTIVE

To estimate the association between different oral corticosteroid prescribing patterns and appropriate fracture preventive care, including treatment with fracture preventive care medications, among older adults with high cumulative oral corticosteroid exposure.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study included 65 195 participants with UK electronic medical record data from the Clinical Practice Research Datalink (January 2, 1998, to January 31, 2020) and 28 674 participants with Ontario, Canada, health administrative data from ICES (April 1, 2002, to September 30, 2020). Participants were adults 66 years or older with eczema, asthma, or chronic obstructive pulmonary disease receiving prescriptions for oral corticosteroids with cumulative prednisolone equivalent doses of 450 mg or higher within 6 months. Data were analyzed October 22, 2020, to September 6, 2022.

EXPOSURES

Participants with prescriptions crossing the 450-mg cumulative oral corticosteroid threshold in less than 90 days were classified as having high-intensity prescriptions, and participants crossing the threshold in 90 days or more as having low-intensity prescriptions. Multiple alternative exposure definitions were used in sensitivity analyses.

MAIN OUTCOMES AND MEASURES

The primary outcome was prescribed fracture preventive care. A secondary outcome was major osteoporotic fracture. Individuals were followed up from the date they crossed the cumulative oral corticosteroid threshold until their outcome or the end of follow-up (up to 1 year after index date). Rates were calculated for fracture preventive care and fractures, and hazard ratios (HRs) were estimated from Cox proportional hazards regression models comparing high- vs low-intensity oral corticosteroid prescriptions.

RESULTS

In both the UK cohort of 65 195 participants (mean [IQR] age, 75 [71-81] years; 32 981 [50.6%] male) and the Ontario cohort of 28 674 participants (mean [IQR] age, 73 [69-79] years; 17 071 [59.5%] male), individuals with high-intensity oral corticosteroid prescriptions had substantially higher rates of fracture preventive care than individuals with low-intensity prescriptions (UK: 134 vs 57 per 1000 person-years; crude HR, 2.34; 95% CI, 2.19-2.51, and Ontario: 73 vs 48 per 1000 person-years; crude HR, 1.49; 95% CI, 1.29-1.72). People with high- and low-intensity oral corticosteroid prescriptions had similar rates of major osteoporotic fractures (UK: crude rates, 14 vs 13 per 1000 person-years; crude HR, 1.07; 95% CI, 0.98-1.15 and Ontario: crude rates, 20 vs 23 per 1000 person-years; crude HR, 0.87; 95% CI, 0.79-0.96). Results from sensitivity analyses suggested that reaching a high cumulative oral corticosteroid dose within a shorter time, with fewer prescriptions, or with fewer or shorter gaps between prescriptions, increased fracture preventive care prescribing.

CONCLUSIONS

The results of this cohort study suggest that older adults prescribed high cumulative oral corticosteroids across multiple prescriptions, or with many or long gaps between prescriptions, may be missing opportunities for fracture preventive care.

摘要

重要性

对于接受高累积口服皮质类固醇剂量处方的复发性缓解型疾病(如湿疹、哮喘和慢性阻塞性肺疾病)患者,识别和减轻骨折预防护理方面的可改变差距,可能会降低与骨折相关的发病率和死亡率。

目的

评估不同的口服皮质类固醇处方模式与适当的骨折预防护理之间的关联,包括骨折预防护理药物的治疗,在高累积口服皮质类固醇暴露的老年患者中。

设计、地点和参与者:这项队列研究包括来自英国临床实践研究数据链接(1998 年 1 月 2 日至 2020 年 1 月 31 日)的 65195 名参与者和来自加拿大安大略省健康管理数据的 28674 名参与者(2002 年 4 月 1 日至 2020 年 9 月 30 日)。参与者为年龄在 66 岁或以上、接受累积泼尼松龙等效剂量为 450mg 或更高的口服皮质类固醇处方的成人,且在 6 个月内处方超过 450mg 累积口服皮质类固醇的阈值。数据于 2020 年 10 月 22 日分析,截至 2022 年 9 月 6 日。

暴露情况

在不到 90 天内越过 450mg 累积口服皮质类固醇阈值的参与者被归类为高强度处方,在 90 天或更长时间内越过阈值的参与者被归类为低强度处方。在敏感性分析中使用了多种替代暴露定义。

主要结果和措施

主要结果是规定的骨折预防护理。次要结果是主要骨质疏松性骨折。从患者越过累积口服皮质类固醇阈值之日起至出现结果或随访结束(索引日期后 1 年)对患者进行随访。计算骨折预防护理和骨折的发生率,并使用 Cox 比例风险回归模型从高与低强度口服皮质类固醇处方比较估计危险比(HR)。

结果

在英国队列的 65195 名参与者(平均[IQR]年龄 75[71-81]岁;32981[50.6%]男性)和安大略队列的 28674 名参与者(平均[IQR]年龄 73[69-79]岁;17071[59.5%]男性)中,高强度口服皮质类固醇处方的患者骨折预防护理的发生率明显高于低强度处方的患者(英国:每 1000 人年 134 比 57;粗 HR,2.34;95%CI,2.19-2.51,安大略:每 1000 人年 73 比 48;粗 HR,1.49;95%CI,1.29-1.72)。高、低强度口服皮质类固醇处方的患者主要骨质疏松性骨折的发生率相似(英国:粗率,每 1000 人年 14 比 13;粗 HR,1.07;95%CI,0.98-1.15;安大略:粗率,每 1000 人年 20 比 23;粗 HR,0.87;95%CI,0.79-0.96)。敏感性分析结果表明,在更短的时间内达到更高的累积口服皮质类固醇剂量、处方次数更少、或处方之间的间隙更少或更长,会增加骨折预防护理的处方。

结论

这项队列研究的结果表明,接受多次处方或多次处方之间存在较大间隙的高累积口服皮质类固醇的老年患者,可能错过了骨折预防护理的机会。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5339/10413212/0c57a7b01dc0/jamadermatol-e232495-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5339/10413212/0c57a7b01dc0/jamadermatol-e232495-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5339/10413212/0c57a7b01dc0/jamadermatol-e232495-g001.jpg

相似文献

1
Association of Different Prescribing Patterns for Oral Corticosteroids With Fracture Preventive Care Among Older Adults in the UK and Ontario.英国和安大略省老年人口服皮质类固醇不同处方模式与骨折预防护理的关联。
JAMA Dermatol. 2023 Sep 1;159(9):961-969. doi: 10.1001/jamadermatol.2023.2495.
2
Atopic Eczema-Associated Fracture Risk and Oral Corticosteroids: A Population-Based Cohort Study.特应性皮炎相关骨折风险与口服皮质类固醇:一项基于人群的队列研究。
J Allergy Clin Immunol Pract. 2022 Jan;10(1):257-266.e8. doi: 10.1016/j.jaip.2021.09.026. Epub 2021 Sep 24.
3
Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice.COPD 患者 GOLD A/B 初始吸入皮质类固醇使用的决定因素:英国普通实践的回顾性研究。
NPJ Prim Care Respir Med. 2017 Jun 29;27(1):43. doi: 10.1038/s41533-017-0040-z.
4
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
5
Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform.在使用 OpenSAFELY 平台的观察性队列研究中,接受吸入皮质类固醇治疗的慢性阻塞性肺疾病或哮喘患者发生 COVID-19 相关死亡的风险。
Lancet Respir Med. 2020 Nov;8(11):1106-1120. doi: 10.1016/S2213-2600(20)30415-X. Epub 2020 Sep 24.
6
Mortality and Morbidity Effects of Long-Term Exposure to Low-Level PM, BC, NO, and O: An Analysis of European Cohorts in the ELAPSE Project.长期暴露于低水平 PM、BC、NO 和 O 对死亡率和发病率的影响:ELAPSE 项目中欧洲队列的分析。
Res Rep Health Eff Inst. 2021 Sep;2021(208):1-127.
7
Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results.慢性阻塞性肺疾病药物治疗:一项历史非干预性队列研究,与 RCT 结果相验证。
Health Technol Assess. 2021 Aug;25(51):1-70. doi: 10.3310/hta25510.
8
Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK.COVID-19 住院患者伴有基础呼吸系统疾病的不良结局风险:一项全国性、多中心前瞻性队列研究,使用 ISARIC WHO 临床特征化方案 UK。
Lancet Respir Med. 2021 Jul;9(7):699-711. doi: 10.1016/S2213-2600(21)00013-8. Epub 2021 Mar 4.
9
Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma.肌肉注射与口服皮质类固醇用于减少急性哮喘患者从急诊科出院后的复发情况。
Cochrane Database Syst Rev. 2018 Jun 2;6(6):CD012629. doi: 10.1002/14651858.CD012629.pub2.
10
Does influenza vaccination increase consultations, corticosteroid prescriptions, or exacerbations in subjects with asthma or chronic obstructive pulmonary disease?流感疫苗接种会增加哮喘或慢性阻塞性肺疾病患者的门诊就诊次数、皮质类固醇处方量或病情加重情况吗?
Thorax. 2003 Oct;58(10):835-9. doi: 10.1136/thorax.58.10.835.

引用本文的文献

1
A Dose of Reality About Dose-Response Relationships.剂量-反应关系的一剂现实。
J Gen Intern Med. 2023 Dec;38(16):3604-3609. doi: 10.1007/s11606-023-08395-x. Epub 2023 Oct 2.

本文引用的文献

1
2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.2022 年美国风湿病学会糖皮质激素诱导性骨质疏松症预防和治疗指南。
Arthritis Rheumatol. 2023 Dec;75(12):2088-2102. doi: 10.1002/art.42646. Epub 2023 Oct 16.
2
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).Lebrikizumab 联合局部皮质类固醇治疗青少年和成人中重度特应性皮炎的疗效和安全性:一项随机临床试验(ADhere)。
JAMA Dermatol. 2023 Feb 1;159(2):182-191. doi: 10.1001/jamadermatol.2022.5534.
3
Atopic Eczema-Associated Fracture Risk and Oral Corticosteroids: A Population-Based Cohort Study.
特应性皮炎相关骨折风险与口服皮质类固醇:一项基于人群的队列研究。
J Allergy Clin Immunol Pract. 2022 Jan;10(1):257-266.e8. doi: 10.1016/j.jaip.2021.09.026. Epub 2021 Sep 24.
4
Prescription Patterns in Patients with Chronic Obstructive Pulmonary Disease and Osteoporosis.慢性阻塞性肺疾病和骨质疏松症患者的处方模式。
Int J Chron Obstruct Pulmon Dis. 2021 Mar 25;16:761-769. doi: 10.2147/COPD.S289799. eCollection 2021.
5
Association of Potent and Very Potent Topical Corticosteroids and the Risk of Osteoporosis and Major Osteoporotic Fractures.强效和超强效外用皮质类固醇与骨质疏松症和主要骨质疏松性骨折风险的关联。
JAMA Dermatol. 2021 Mar 1;157(3):275-282. doi: 10.1001/jamadermatol.2020.4968.
6
Glucocorticoid-induced osteoporosis: an update.糖皮质激素性骨质疏松症:更新。
Endocrine. 2018 Jul;61(1):7-16. doi: 10.1007/s12020-018-1588-2. Epub 2018 Apr 24.
7
Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement.特应性皮炎全身性皮质类固醇激素的应用:国际特应性皮炎理事会共识声明。
Br J Dermatol. 2018 Mar;178(3):768-775. doi: 10.1111/bjd.15928. Epub 2018 Jan 28.
8
Prescriptions for atopic dermatitis: oral corticosteroids remain commonplace.特应性皮炎的处方:口服糖皮质激素仍然很常见。
J Dermatolog Treat. 2018 May;29(3):238-240. doi: 10.1080/09546634.2017.1365112. Epub 2017 Oct 2.
9
Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in France.成人口服糖皮质激素的患病率及处方模式:法国的一项回顾性横断面和队列分析
BMJ Open. 2017 Jul 31;7(7):e015905. doi: 10.1136/bmjopen-2017-015905.
10
Negative Control Outcomes: A Tool to Detect Bias in Randomized Trials.阴性对照结果:一种检测随机试验中偏倚的工具。
JAMA. 2016 Dec 27;316(24):2597-2598. doi: 10.1001/jama.2016.17700.